Epidemiology, treatment and outcomes of bloodstream infection due to vancomycin-resistant enterococci in cancer patients in a vanB endemic setting.

MLA

Xie, Ouli, et al. “Epidemiology, Treatment and Outcomes of Bloodstream Infection Due to Vancomycin-Resistant Enterococci in Cancer Patients in a VanB Endemic Setting.” BMC Infectious Diseases, vol. 20, no. 1, Mar. 2020, p. 228. EBSCOhost, https://doi.org/10.1186/s12879-020-04952-5.

APA

Xie, O., Slavin, M. A., Teh, B. W., Bajel, A., Douglas, A. P., & Worth, L. J. (2020). Epidemiology, treatment and outcomes of bloodstream infection due to vancomycin-resistant enterococci in cancer patients in a vanB endemic setting. BMC Infectious Diseases, 20(1), 228. https://doi.org/10.1186/s12879-020-04952-5

Chicago

Xie, Ouli, Monica A Slavin, Benjamin W Teh, Ashish Bajel, Abby P Douglas, and Leon J Worth. 2020. “Epidemiology, Treatment and Outcomes of Bloodstream Infection Due to Vancomycin-Resistant Enterococci in Cancer Patients in a VanB Endemic Setting.” BMC Infectious Diseases 20 (1): 228. doi:10.1186/s12879-020-04952-5.